XGN|Exagen Inc|Price:3.510|Chg%:0.15

More Details of Exagen Inc Company

Exagen Inc. is a provider of autoimmune diagnostics focused on transforming care for patients with chronic and debilitating autoimmune conditions. The Company is focused on the design, development and commercialization of a portfolio of testing products under its AVISE brand, which allow for the differential diagnosis, prognosis and monitoring of complex rheumatic, autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its testing products are supported by two proprietary technologies: its AVISE Lupus platform, which incorporates Cell-Bound Complement Activation Products (CB-CAPs) for diagnosing SLE, and a set of three biomarkers, the t-cell-based CB-CAP TC4d, along with two t-cell antibodies, TIgG, and TIgM (the T-Cell Biomarkers), all of which are incorporated into its AVISE CTD product. The Company’s flagship product, AVISE CTD, enables clinicians to more effectively diagnose complex autoimmune conditions.

Exagen Inc Info



Ticker SymbolXGN

Company nameExagen Inc

IPO dateSep 19, 2019

CEOAballi (John)

Number of employees203

Security typeOrdinary Share

Fiscal year-endSep 19

Address1261 Liberty Way

CityVISTA

Stock exchangeNASDAQ OMX - NASDAQ BASIC

CountryUnited States of America

Postal code92081

Phone17605601501

Websitehttps://exagen.com/

Ticker SymbolXGN

IPO dateSep 19, 2019

CEOAballi (John)

Company Executives of Exagen Inc



Name

Name/Position

Position

Shareholding

Change

Mr. John Aballi

President, Chief Executive Officer, Director

336.08K

-31787.00%

Dr. Tina Susan Nova, Ph.D.

Executive Chairman of the Board

54.11K

+54113.00%

Ms. Ana Hooker

Independent Director

33.00K

+33000.00%

Mr. Jeffrey G. (Jeff) Black

Chief Financial Officer, Corporate Secretary

29.03K

-20466.00%

Mr. Paul Kim, CPA

Independent Director

8.33K

+8333.00%

Dr. Bruce C. Robertson, Ph.D.

Independent Director

--

Mr. Frank Stokes

Independent Director

--

Dr. Scott D. Kahn, Ph.D.

Independent Director

--

Mr. Charles S. (Chas) Mckhann

Independent Director

--

Name

Name/Position

Position

Shareholding

Change

Mr. John Aballi

President, Chief Executive Officer, Director

336.08K

-31787.00%

Dr. Tina Susan Nova, Ph.D.

Executive Chairman of the Board

54.11K

+54113.00%

Ms. Ana Hooker

Independent Director

33.00K

+33000.00%

Mr. Jeffrey G. (Jeff) Black

Chief Financial Officer, Corporate Secretary

29.03K

-20466.00%

Mr. Paul Kim, CPA

Independent Director

8.33K

+8333.00%

Dr. Bruce C. Robertson, Ph.D.

Independent Director

--

Revenue Breakdown

Currency: USDUpdated: Tue, Jan 6

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

By BusinessUSD

Name

Revenue

Proportion

Commercial

9.45M

54.82%

Government

3.99M

23.13%

Client

3.73M

21.65%

Other

69.00K

0.40%

Relevant data have not been disclosed by the company yet.

By Business

By Region

By BusinessUSD

Name

Revenue

Proportion

Commercial

9.45M

54.82%

Government

3.99M

23.13%

Client

3.73M

21.65%

Other

69.00K

0.40%

Shareholding Stats

Updated: Fri, Feb 6

Shareholders

Shareholder Types

Shareholders

Proportion

Tullis Health Investors

7.97%

NMSIC Co-Investment Fund, L.P

7.76%

RTW Investments L.P.

7.49%

H.I.G. Capital, LLC

7.48%

Chernett (Jorey)

5.43%

Other

63.86%

Shareholders

Proportion

Tullis Health Investors

7.97%

NMSIC Co-Investment Fund, L.P

7.76%

RTW Investments L.P.

7.49%

H.I.G. Capital, LLC

7.48%

Chernett (Jorey)

5.43%

Other

63.86%

Shareholder Types

Shareholders

Proportion

Investment Advisor/Hedge Fund

14.41%

Investment Advisor

12.87%

Corporation

11.42%

Hedge Fund

11.09%

Individual Investor

8.62%

Venture Capital

8.09%

Private Equity

7.48%

Research Firm

1.56%

Pension Fund

0.62%

Other

23.84%

Institutional Shareholding



Updated: Wed, Jan 21

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2026Q4

100

12.69M

58.04%

--

2025Q4

112

12.69M

55.99%

-929.44K

2025Q3

94

13.30M

58.71%

+2.23M

2025Q2

80

14.11M

64.13%

-1.92M

2025Q1

76

14.50M

73.21%

-473.27K

2024Q4

75

14.52M

82.35%

-157.43K

2024Q3

78

15.24M

87.35%

-674.41K

2024Q2

89

14.88M

85.44%

-1.05M

2024Q1

115

14.74M

85.49%

-1.97M

2023Q4

122

14.89M

86.95%

-2.20M

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

Tullis Health Investors

1.81M

7.97%

--

Apr 15, 2025

NMSIC Co-Investment Fund, L.P

1.76M

7.76%

-350.00K

-16.60%

Mar 25, 2025

RTW Investments L.P.

1.70M

7.49%

--

Sep 30, 2025

H.I.G. Capital, LLC

1.70M

7.48%

--

Apr 15, 2025

Hunt Holdings, L.P

829.28K

3.66%

-182.04K

-18.00%

Dec 12, 2024

The Vanguard Group, Inc.

733.82K

3.24%

+52.20K

+7.66%

Sep 30, 2025

Balyasny Asset Management LP

723.43K

3.19%

+4.65K

+0.65%

Sep 30, 2025

Invesco Capital Management LLC

675.19K

2.98%

+669.73K

+12257.10%

Sep 30, 2025

Kennedy Capital Management LLC

551.85K

2.44%

+241.13K

+77.60%

Sep 30, 2025

Related ETFs



Updated: Sat, Dec 6

Name

Proportion

Invesco Dorsey Wright SmallCap Momentum ETF

1.13%

Invesco NASDAQ Future Gen 200 ETF

0.64%

Lattice Hartford Multifactor Small Cap ETF

0.37%

iShares Micro-Cap ETF

0.03%

DFA Dimensional US Sustainability Core 1 ETF

0%

Dimensional US Core Equity 1 ETF

0%

Invesco Dorsey Wright SmallCap Momentum ETF

Proportion1.13%

Invesco NASDAQ Future Gen 200 ETF

Proportion0.64%

Lattice Hartford Multifactor Small Cap ETF

Proportion0.37%

iShares Micro-Cap ETF

Proportion0.03%

DFA Dimensional US Sustainability Core 1 ETF

Proportion0%

Dimensional US Core Equity 1 ETF

Proportion0%

Dividend



A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Splits



Date

Ex-dividend Date

Type

Ratio

No Data

Date

Ex-dividend Date

Type

Ratio

No Data